Quantcast

Latest Kidney transplantation Stories

2014-08-20 16:24:51

HORSHOLM, Denmark, Aug. 20, 2014 /PRNewswire/ -- Highlights: -- On 28 July the European Commission granted marketing authorization for Envarsus® for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union (EU). -- Following the European marketing authorization Veloxis will receive a milestone payment of USD 15 million from our European partner Chiesi in the third quarter 2014 which is in line with...

2014-08-16 16:21:00

OTTAWA, Aug. 16, 2014 /CNW/ - Apotex, in consultation with Health Canada, is recalling one lot (KY6601) of Apo-Mycophenolic Acid due to a package labelling error. The product is used to prevent organ rejection in patients receiving a kidney transplant. The French statement on the outer carton indicates that each tablet contains 180 mg of the medicine. The actual tablets in the package contain the correct strength of 360 mg. The rest of the carton, the leaflets, the blister...

2014-07-30 12:30:36

Findings presented at the 2014 World Transplant Congress SAN FRANCISCO, July 30, 2014 /PRNewswire/ -- A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. C1-INH is a human protein and an important inhibitor of the complement system. http://photos.prnewswire.com/prnvar/20100914/PH63692LOGO The...

2014-07-28 13:28:02

University of Oxford Oxford University scientists have shown that a powerful drug given at the time of a kidney transplant operation not only halves the early risk of rejection, but that it also allows a less toxic regimen of anti-rejection drugs to be used after the operation. The key results are reported in The Lancet and presented at the World Transplant Congress in San Francisco today. They will help doctors faced with a difficult transplant conundrum: the powerful combinations of...

2014-07-28 12:27:34

TOTOWA, N.J., July 28, 2014 /PRNewswire/ -- BiologicTx(®) announced their Discovery 2 Life((TM)) (D2L((TM))), a leading digital health platform designed to guide and support hospitals, clinicians and patients throughout the organ transplant continuum. D2L supports aspects of the organ transplant process, including organization of data associated with enrolling a transplant candidate into a desensitization therapeutic program, donor data management (including identifying optimal...

2014-07-23 16:27:28

LONDON, July 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Renal Dialysis Equipment: Technologies and Global Marketshttps://www.reportbuyer.com/product/2070056/Renal-Dialysis-Equipment-Technologies-and-Global-Markets.htmlREPORT HIGHLIGHTSThe global market for dialysis equipment and accessories was valued at $12.5 billion in 2012 and $13.4 billion in 2013. This market is expected to be valued at nearly $18.8 billion in 2018, rising at a five-year...

2014-07-22 12:30:00

3-Way Kidney Transplant Donor/Recipient Pairs Identified Using BiologicTx's Matchgrid Software TOTOWA, N.J., July 22, 2014 /PRNewswire/ -- BiologicTx(®) today announced their participation in Florida's first 3-way Kidney Paired Donation transplant exchange utilizing BiologicTx's proprietary matching software, Matchgrid(TM). The landmark surgical procedures happened on July 9 at the Miami Transplant Institute, located at Jackson Memorial Hospital in Miami, Fla....

2014-07-18 12:00:52

American Society of Nephrology Living kidney donation rates dropping among low income populations in the US The decline in living kidney donation over the past several years has been concerning and is poorly understood. A study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN) identifies low income as an important barrier to living donation, and more importantly, implies that this barrier is becoming more difficult to overcome over time. The...

2014-07-17 12:29:58

TOTOWA, N.J., July 17, 2014 /PRNewswire/ -- BiologicTx(®) was selected as the specialty pharmacy for the observational treatment registry study to evaluate the long-term treatment effects of immune globulin intravenous (IGIV) maintenance therapy on donor specific antibodies (DSA) in renal transplant recipients. Study sponsors are Databean of Mount Vernon, NY and eMax Health of White Plains, NY. http://photos.prnewswire.com/prnvar/20130520/LA16505LOGO The clinical trial involves ten...

2014-07-16 12:27:25

NxStage Patient Advocates to travel the East Coast to share the benefits of home hemodialysis LAWRENCE, Mass., July 16, 2014 /PRNewswire/ -- NxStage® Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, announced today the launch of the NxStage Freedom Tour, a two week road trip in a recreational vehicle to promote and educate dialysis patients on the benefits of home hemodialysis with the NxStage System One(TM). Traveling in the NxStage Freedom...


Latest Kidney transplantation Reference Libraries

2011-01-05 16:14:54

The BK virus, a member of the polyomavirus family, has no major consequences of infected except with those that are immunocomprimised or immunosuppressed. The virus was first isolated in 1971 from the urine sample of a renal transplant patient whose initials were B.K. Similar in genome sequences to the JCV virus they are most easily identified and differentiated from each other through serological tests using specific antibodies or through PCR based genotyping approach. Most people are...

More Articles (1 articles) »
Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.